Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03972124 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Cannabis for the Prophylactic Treatment of Migraine

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial status: Not Yet Recruiting to Recruiting
    • Enrollment target: 120 to 72
    • Primary and study completion dates: Jun 2026 to Dec 2028
    • Start date changed from estimate of Jun 2024 to Apr 1, 2026
    v8
  2. Primary completion date: Dec 2023 to Jun 2026
    • Start date: Jun 2022 to Jun 2024
    • Study completion date: Jun 2024 to Jun 2026
    v7
  3. Start date: Oct 2021 to Jun 2022v6
  4. Interventions: CBD 100 mg BID (Drug), CBD 50 mg BID (Drug), Placebo (Drug) to CBD 100 mg OD (Drug), CBD 200 mg OD (Drug), Placebo (Drug)v5
  5. Re-verified, no change to tracked fieldsv4
Show 2 earlier versionsHide 2 earlier versions
  1. Primary completion date: Dec 2021 to Dec 2023
    • Start date: Oct 2019 to Oct 2021
    • Study completion date: Jun 2022 to Jun 2024
    v3
  2. Secondary endpoints revised (10)v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
University of Calgary
208 trials monitored
See 5 trials at risk
Migraine
482 trials monitored
See 26 trials at risk
This study will evaluate the efficacy and safety of cannabis for the treatment of chronic migraine headaches. Study subjects will be randomized to one of three groups: lower dose CBD, higher dose CBD or placebo.
Trial Details
NCT Number NCT03972124
Lead Sponsor University of Calgary
Conditions
(from sponsor)		 Chronic Migraine
Enrollment 72 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov